Literature DB >> 15798662

Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data.

Nahum Méndez-Sánchez1, Antonio R Villa, Norberto C Chávez-Tapia, Guadalupe Ponciano-Rodriguez, Paloma Almeda-Valdés, Daniela González, Misael Uribe.   

Abstract

BACKGROUND AND AIMS: The epidemiology of liver cirrhosis differs across sex, ethnic groups, and geographic regions. In 2000, chronic liver disease was the fifth leading cause of death in Mexico. Accurate knowledge of the demographics of liver disease is essential in formulating health-care policies. Our main aim was to project the trends in liver disease prevalence in Mexico from 2005 to 2050 based on mortality data.
METHODS: Data on national mortality reported for the year 2002 in Mexico were analyzed. Specific-cause mortality rates were calculated for a selected age population (> 25 years old) and classified by sex and projected year (2005-2050). The following codes of the International Classification of Diseases for liver diseases were included: non-alcoholic chronic liver disease and cirrhosis, alcoholic liver disease, liver cancer, and acute and chronic hepatitis B and C infection. The projected prevalence of a chronic liver disease was estimated using the following equation: P = (ID x T) / [(ID xT) + 1], where P = prevalence, ID = incidence density (mortality rate multiplied by 2), T = median survival with the disease (= 20 years).
RESULTS: Nearly two million cases of chronic liver disease are expected. Alcohol-related liver diseases remain the most important causes of chronic liver disease, accounting for 996,255 cases in 2050. An emergent syndrome is non-alcoholic liver disease, which will be more important that infectious liver diseases (823,366 vs 46,992 expected cases, respectively). Hepatocellular carcinoma will be the third leading cause of liver disease.
CONCLUSIONS: Chronic liver disease will be an important cause of morbidity and mortality in the future. Preventive strategies are necessary, particularly those related to obesity and alcohol consumption, to avoid catastrophic consequences.

Entities:  

Mesh:

Year:  2005        PMID: 15798662

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  16 in total

Review 1.  Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.

Authors:  Norberto-C Chavez-Tapia; Tonatiuh Barrientos-Gutierrez; Felix-I Tellez-Avila; Francisco Sanchez-Avila; Maria-Antonieta Montano-Reyes; Misael Uribe
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 2.  Hepatocellular Carcinoma in Mexico.

Authors:  Laura Esthela Cisneros Garza; Ignacio Aiza Haddad
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-03-10

3.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

4.  Hepatitis and liver disease knowledge and preventive practices among health workers in Mexico: a cross-sectional study.

Authors:  Noreen Islam; Yvonne N Flores; Paula Ramirez; Roshan Bastani; Jorge Salmerón
Journal:  Int J Public Health       Date:  2013-10-06       Impact factor: 3.380

Review 5.  Bariatric surgery for non-alcoholic steatohepatitis in obese patients.

Authors:  Norberto C Chavez-Tapia; Felix I Tellez-Avila; Tonatiuh Barrientos-Gutierrez; Nahum Mendez-Sanchez; Javier Lizardi-Cervera; Misael Uribe
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

6.  Longitudinal association of obesity, metabolic syndrome and diabetes with risk of elevated aminotransferase levels in a cohort of Mexican health workers.

Authors:  Yvonne N Flores; Allyn Auslander; Catherine M Crespi; Michael Rodriguez; Zuo-Feng Zhang; Francisco Durazo; Jorge Salmerón
Journal:  J Dig Dis       Date:  2016-05       Impact factor: 2.325

7.  Nuclear receptors in nonalcoholic Fatty liver disease.

Authors:  Jorge A López-Velázquez; Luis D Carrillo-Córdova; Norberto C Chávez-Tapia; Misael Uribe; Nahum Méndez-Sánchez
Journal:  J Lipids       Date:  2011-12-08

Review 8.  Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis.

Authors:  Camila Ribeiro de Avelar; Emile Miranda Pereira; Priscila Ribas de Farias Costa; Rosângela Passos de Jesus; Lucivalda Pereira Magalhães de Oliveira
Journal:  World J Gastroenterol       Date:  2017-07-21       Impact factor: 5.742

9.  The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer.

Authors:  Nahum Méndez-Sánchez; Alejandro Valencia-Rodriguez; Alfonso Vera-Barajas; Ludovico Abenavoli; Emidio Scarpellini; Guadalupe Ponciano-Rodriguez; David Q-H Wang
Journal:  Hepatoma Res       Date:  2020-02-20

10.  Age-standardized mortality rates related to viral hepatitis in Brazil.

Authors:  Hugo Perazzo; Antonio G Pacheco; Paula M Luz; Rodolfo Castro; Chris Hyde; Juliana Fittipaldi; Caroline Rigolon; Sandra W Cardoso; Beatriz Grinsztejn; Valdiléa G Veloso
Journal:  BMC Infect Dis       Date:  2017-07-31       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.